BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Vetter M, Neurath MF. Emerging oral targeted therapies in inflammatory bowel diseases: opportunities and challenges. Therap Adv Gastroenterol 2017;10:773-90. [PMID: 29051788 DOI: 10.1177/1756283X17727388] [Cited by in Crossref: 18] [Cited by in F6Publishing: 6] [Article Influence: 3.6] [Reference Citation Analysis]
Number Citing Articles
1 Yadav A, Vasquez P, Dolgin NH, Falchuk KR, Feuerstein JD. Variations in Insurance Policies Regarding Adherence to the AGA Guideline for Therapeutic Drug Monitoring in IBD. J Clin Gastroenterol 2019;53:e239-42. [PMID: 30439759 DOI: 10.1097/MCG.0000000000001144] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
2 Lai H, Yang Z, Lou Z, Li F, Xie F, Pan W, Xu C, Zhang L, Zhang S, Zhang L, Huang M. Root Extract of Lindera aggregata (Sims) Kosterm. Modulates the Th17/Treg Balance to Attenuate DSS-Induced Colitis in Mice by IL-6/STAT3 Signaling Pathway. Front Pharmacol 2021;12:615506. [PMID: 34093175 DOI: 10.3389/fphar.2021.615506] [Reference Citation Analysis]
3 Decara J, Rivera P, López-Gambero AJ, Serrano A, Pavón FJ, Baixeras E, Rodríguez de Fonseca F, Suárez J. Peroxisome Proliferator-Activated Receptors: Experimental Targeting for the Treatment of Inflammatory Bowel Diseases. Front Pharmacol 2020;11:730. [PMID: 32536865 DOI: 10.3389/fphar.2020.00730] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
4 Kwong EK, Zhou H. Sphingosine-1-phosphate signaling and the gut-liver axis in liver diseases. Liver Res 2019;3:19-24. [PMID: 31360579 DOI: 10.1016/j.livres.2019.02.003] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
5 Pagnini C, Pizarro TT, Cominelli F. Novel Pharmacological Therapy in Inflammatory Bowel Diseases: Beyond Anti-Tumor Necrosis Factor. Front Pharmacol. 2019;10:671. [PMID: 31316377 DOI: 10.3389/fphar.2019.00671] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 10.7] [Reference Citation Analysis]
6 Kikut J, Konecka N, Ziętek M, Kulpa D, Szczuko M. Diet supporting therapy for inflammatory bowel diseases. Eur J Nutr 2021;60:2275-91. [PMID: 33788019 DOI: 10.1007/s00394-021-02489-0] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Sukocheva OA, Furuya H, Ng ML, Friedemann M, Menschikowski M, Tarasov VV, Chubarev VN, Klochkov SG, Neganova ME, Mangoni AA, Aliev G, Bishayee A. Sphingosine kinase and sphingosine-1-phosphate receptor signaling pathway in inflammatory gastrointestinal disease and cancers: A novel therapeutic target. Pharmacol Ther 2020;207:107464. [PMID: 31863815 DOI: 10.1016/j.pharmthera.2019.107464] [Cited by in Crossref: 40] [Cited by in F6Publishing: 37] [Article Influence: 13.3] [Reference Citation Analysis]
8 Burrows K, Ngai L, Wong F, Won D, Mortha A. ILC2 Activation by Protozoan Commensal Microbes. Int J Mol Sci 2019;20:E4865. [PMID: 31574995 DOI: 10.3390/ijms20194865] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]